The Prognostic Impact of Myocardial Late Gadolinium Enhancement

J 2014

The Prognostic Impact of Myocardial Late Gadolinium Enhancement

PANOVSKÝ, Roman, Martin PLEVA, Věra FEITOVÁ, Peter KRUŽLIAK, Jaroslav MELUZÍN et. al.

Základní údaje

Originální název

The Prognostic Impact of Myocardial Late Gadolinium Enhancement

Autoři

PANOVSKÝ, Roman (203 Česká republika, garant, domácí), Martin PLEVA (203 Česká republika), Věra FEITOVÁ (203 Česká republika), Peter KRUŽLIAK (203 Česká republika), Jaroslav MELUZÍN (203 Česká republika, domácí) a Vladimír KINCL (203 Česká republika, domácí)

Vydání

CARDIOLOGY IN REVIEW, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2014, 1061-5377

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.407

Kód RIV

RIV/00216224:14110/14:00076100

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1097/CRD.0000000000000002

UT WoS

000334321000003

Klíčová slova anglicky

cardiovascular magnetic resonance; prognosis; late gadolinium enhancement

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 8. 2014 15:25, Soňa Böhmová

Anotace

V originále

Cardiovascular magnetic resonance using late gadolinium enhancement (LGE) provides a unique opportunity to assess myocardial tissue in vivo. LGE enables tissue characterization in ischemic and nonischemic cardiomyopathies and other cardiac diseases. LGE is associated with adverse clinical outcomes across a range of different cardiac conditions and may improve risk stratification for death, sudden cardiac death, or serious adverse events beyond traditional prognostic markers. Generally, matching data for the prognostic impact of LGE are frequently reached in cardiac disorders. In other diseases, only a limited number of trials are available, but it is anticipated that the prognostic impact of delayed enhancement will become evident. The development and validation of new cardiovascular magnetic resonance methods for diffuse myocardial fibrosis measurements would even improve the prognostic impact of LGE. The evaluation of diffuse myocardial fibrosis has a great potential in large-scale diseases, including their initial phases, with the possibility to identify patients at risk for subsequent development of clinical heart failure, to assess repeatedly the stage and progression of cardiac diseases, and to monitor the effect of treatment.

Citovat

PANOVSKÝ, Roman, Martin PLEVA, Věra FEITOVÁ, Peter KRUŽLIAK, Jaroslav MELUZÍN a Vladimír KINCL. The Prognostic Impact of Myocardial Late Gadolinium Enhancement. CARDIOLOGY IN REVIEW. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2014, roč. 22, č. 3, s. 128-139. ISSN 1061-5377. Dostupné z: https://dx.doi.org/10.1097/CRD.0000000000000002.

@article{1194377,
   author = {Panovský, Roman and Pleva, Martin and Feitová, Věra and Kružliak, Peter and Meluzín, Jaroslav and Kincl, Vladimír},
   article_location = {PHILADELPHIA},
   article_number = {3},
   doi = {http://dx.doi.org/10.1097/CRD.0000000000000002},
   keywords = {cardiovascular magnetic resonance; prognosis; late gadolinium enhancement},
   language = {eng},
   issn = {1061-5377},
   journal = {CARDIOLOGY IN REVIEW},
   title = {The Prognostic Impact of Myocardial Late Gadolinium Enhancement},
   volume = {22},
   year = {2014}
}

TY  - JOUR
ID  - 1194377
AU  - Panovský, Roman - Pleva, Martin - Feitová, Věra - Kružliak, Peter - Meluzín, Jaroslav - Kincl, Vladimír
PY  - 2014
TI  - The Prognostic Impact of Myocardial Late Gadolinium Enhancement
JF  - CARDIOLOGY IN REVIEW
VL  - 22
IS  - 3
SP  - 128-139
EP  - 128-139
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 10615377
KW  - cardiovascular magnetic resonance
KW  - prognosis
KW  - late gadolinium enhancement
N2  - Cardiovascular magnetic resonance using late gadolinium enhancement (LGE) provides a unique opportunity to assess myocardial tissue in vivo. LGE enables tissue characterization in ischemic and nonischemic cardiomyopathies and other cardiac diseases. LGE is associated with adverse clinical outcomes across a range of different cardiac conditions and may improve risk stratification for death, sudden cardiac death, or serious adverse events beyond traditional prognostic markers. Generally, matching data for the prognostic impact of LGE are frequently reached in cardiac disorders. In other diseases, only a limited number of trials are available, but it is anticipated that the prognostic impact of delayed enhancement will become evident. The development and validation of new cardiovascular magnetic resonance methods for diffuse myocardial fibrosis measurements would even improve the prognostic impact of LGE. The evaluation of diffuse myocardial fibrosis has a great potential in large-scale diseases, including their initial phases, with the possibility to identify patients at risk for subsequent development of clinical heart failure, to assess repeatedly the stage and progression of cardiac diseases, and to monitor the effect of treatment.
ER  -

PANOVSKÝ, Roman, Martin PLEVA, Věra FEITOVÁ, Peter KRUŽLIAK, Jaroslav MELUZÍN a Vladimír KINCL. The Prognostic Impact of Myocardial Late Gadolinium Enhancement. \textit{CARDIOLOGY IN REVIEW}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{}amp; WILKINS, 2014, roč.~22, č.~3, s.~128-139. ISSN~1061-5377. Dostupné z: https://dx.doi.org/10.1097/CRD.0000000000000002.

Podrobný výpis o publikaci